By Jennifer Ernst, CEO, co-founder Tivic Health
This month, we welcomed three new members to the Tivic Health board of directors: Sheryle Bolton, entrepreneur and former chairman and CEO of Scientific Learning Corporation; Karen Drexler, CEO and board member of Sandstone Diagnostics; and Dean Zikria former global marketing executive at Johnson & Johnson and Pfizer Pharmaceuticals.
These dynamic industry leaders bring a wide range of consumer health and technology experience and will help guide the growth of our company. Our team will directly benefit from their expertise, perspectives and contributions as we scale our commercial operations and develop future bioelectronic therapies. Background on our new board members is below:
Sheryle Bolton is Professor of Entrepreneurship, Hult International Business School. She is an experienced public company CEO, international board member and serial entrepreneur. As CEO and Chairman of Scientific Learning Corporation, a neuroscience technology company, she built the company from pre-product to a highly successful IPO. Previously, she was vice president at Merrill Lynch Capital Markets, and a senior executive at Home Box Office and Rockefeller and Co.
Karen Drexler is CEO and board member of Sandstone Diagnostics with extensive and operational experience building consumer health tech device companies. She founded and ran Amira Medical until its sale to Roche Diabetes Care. She managed a variety of functions across the company at LifeScan and executed the sale of the company to Johnson & Johnson. She has received 11 patents, served on numerous boards and is active in non-profits that support female entrepreneurs.
Dean Zikria brings deep industry experience in allergy and asthma to the Board. He has previously served as CEO of Spirosure, a FeNO detection company for asthma diagnostics. He has also previously served as head of global marketing for Johnson & Johnson’s Animas Corporation within their medical device & diagnostics division. He was head of strategy for Pfizer Pharmaceuticals U.S. Cardiovascular Unit, a division with about $7 billion in annual revenues.
